F
Frank E. Speizer
Researcher at Brigham and Women's Hospital
Publications - 641
Citations - 140522
Frank E. Speizer is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Relative risk & Risk factor. The author has an hindex of 193, co-authored 636 publications receiving 135891 citations. Previous affiliations of Frank E. Speizer include Medical Research Council & Beth Israel Deaconess Medical Center.
Papers
More filters
U.S. Environmental Protection Agency Clean Air Scientific Advisory Committee (CASAC) CASAC Particulate Matter (PM) Review Panel Summary Meeting Minutes of the CASAC PM Review Panel Public Advisory Teleconference
Rogene F. Henderson,Ellis Cowling,J. D. Crapo,Frederick Miller,Frank E. Speizer,Barbara Zielinska,Jane Q. Koenig,Allan Legge,Paul J. Lioy,Morton Lippmann,Joe L. Mauderly,Roger O McClellan,Günter Oberdörster,Sverre Vedal,Ronald White,George T. Wolff,Epa Sab +16 more
Journal ArticleDOI
Questionnaire approaches and analysis of epidemiological data in organic dust lung diseases.
TL;DR: The specific aim of this paper is to describe some of the findings in organic dust lung disease which have been identified with the use of epidemiological approaches and how these approaches might be further put to use in the study of industrial population groups to learn about pulmonary diseases associated with exposure to organic materials.
Journal Article
Ambient air pollution asa risk factor for lung cancer
TL;DR: Observations suggest that the most widely cited estimates of the proportional contribution of air pollution to lung cancer occurrence in the US, based largely on the results of animal experimentation, may be too low.
Journal ArticleDOI
Postmenopausal Estrogen and Progestin Use and the Risk of Cardiovascular Disease
Francine Grodstein,Meir J. Stampfer,JoAnn E. Manson,Graham A. Colditz,Walter C. Willett,Bernard Rosner,Frank E. Speizer,Charles H. Hennekens +7 more
TL;DR: In this article, the authors examined the relation between cardiovascular disease and postmenopausal hormone therapy during up to 16 years of follow-up in 59,337 women from the Nurses' Health Study, who were 30 to 55 years of age at base line.